Oramed Pharmaceuticals Inc. (TLV:ORMP)
888.80
-11.20 (-1.24%)
At close: Dec 4, 2025
Oramed Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Aug '21 Aug 31, 2021 | 2016 - 2020 |
| Net Income | 43.85 | -19.06 | 5.53 | -36.56 | -35 | -22.24 | Upgrade
|
| Depreciation & Amortization | 0.12 | 0.19 | 0.2 | 0.06 | 0.05 | 0.08 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0.01 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 1.04 | Upgrade
|
| Loss (Gain) From Sale of Investments | -65.04 | 7.41 | -16.39 | 0.76 | 0.22 | -0.88 | Upgrade
|
| Stock-Based Compensation | 4.94 | 4.05 | 4.22 | 11.53 | 5.33 | 2.7 | Upgrade
|
| Other Operating Activities | 0.16 | -4.21 | -1.15 | -2.75 | -1.86 | -0.56 | Upgrade
|
| Change in Accounts Payable | -0.18 | 3.53 | -2.23 | -0.38 | 2.07 | 2.06 | Upgrade
|
| Change in Unearned Revenue | -2.25 | - | -1.34 | -0.7 | -2.71 | -2.7 | Upgrade
|
| Change in Other Net Operating Assets | -0.12 | -0.33 | 0.87 | 0.14 | -1.45 | -0.67 | Upgrade
|
| Operating Cash Flow | -10.59 | -8.41 | -10.3 | -27.92 | -33.37 | -21.18 | Upgrade
|
| Capital Expenditures | -0.02 | -0.02 | -0.25 | -0.5 | -0.03 | -0.38 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.02 | - | - | Upgrade
|
| Investment in Securities | 25.51 | 105.9 | -72.78 | 30.69 | -297.72 | 1.61 | Upgrade
|
| Other Investing Activities | -0.07 | -0.07 | - | -0 | - | -25 | Upgrade
|
| Investing Cash Flow | 22.55 | 105.82 | -73.04 | 30.21 | -297.74 | -23.76 | Upgrade
|
| Short-Term Debt Issued | - | - | 99.55 | - | - | - | Upgrade
|
| Total Debt Issued | - | - | 99.55 | - | - | - | Upgrade
|
| Short-Term Debt Repaid | - | -49.55 | -50 | - | - | - | Upgrade
|
| Total Debt Repaid | - | -49.55 | -50 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | - | -49.55 | 49.55 | - | - | - | Upgrade
|
| Issuance of Common Stock | - | - | 2.43 | 11.56 | 181.72 | 101.39 | Upgrade
|
| Repurchase of Common Stock | -1.93 | -2.49 | - | -0.78 | - | - | Upgrade
|
| Other Financing Activities | - | - | - | - | - | 1.5 | Upgrade
|
| Financing Cash Flow | -1.93 | -52.04 | 51.98 | 10.78 | 181.72 | 102.89 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.04 | -0 | -0.05 | -0.06 | 0.03 | 0 | Upgrade
|
| Net Cash Flow | 10.08 | 45.37 | -31.41 | 13.01 | -149.37 | 57.95 | Upgrade
|
| Free Cash Flow | -10.61 | -8.43 | -10.55 | -28.41 | -33.39 | -21.56 | Upgrade
|
| Free Cash Flow Margin | -530.40% | - | -787.24% | -1051.20% | -1231.31% | -797.48% | Upgrade
|
| Free Cash Flow Per Share | -0.25 | -0.21 | -0.26 | -0.73 | -0.90 | -0.76 | Upgrade
|
| Cash Interest Paid | - | 2.32 | 0.57 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 3.32 | - | - | 0.1 | 0.3 | - | Upgrade
|
| Levered Free Cash Flow | -3.23 | -1.51 | -9.68 | -15.75 | - | -9.42 | Upgrade
|
| Unlevered Free Cash Flow | -3.23 | -0.98 | -8.41 | -15.75 | - | -9.42 | Upgrade
|
| Change in Working Capital | 5.38 | 3.2 | -2.7 | -0.94 | -2.1 | -1.32 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.